Short answer
Biohaven Ltd. (BHVN) filed an 8-K current report with the SEC on July 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Bruce Car retires as Chief Scientific Officer July 13, 2026, but remains an executive officer as part-time Chief Innovation Officer.
Biohaven Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Bruce Car retires as Chief Scientific Officer July 13, 2026, but remains an executive officer as part-time Chief Innovation Officer
- Car’s salary reduced 50%, lowering compensation expense while retaining scientific and collaboration expertise
- David Pirman promoted to Executive Vice President and Head of Discovery, assuming leadership of internal drug discovery
- Car continues leading multiple assets under Biohaven’s Bexorg collaboration, preserving external-partnership oversight
Item EX-99.1 · Exhibit EX-99.1
- David Pirman promoted to Executive Vice President and Head of Discovery, leading internal drug-discovery programs
- Bruce Car retiring as Chief Scientific Officer effective July 13, 2026, remaining part-time Chief Innovation Officer
- Car’s new role emphasizes external collaborations, including multiple assets under the Bexorg partnership
- General Counsel Warren Volles designated an executive officer, expanding executive oversight of legal functions
- Leadership realignment preserves Car’s scientific involvement while shifting internal discovery accountability to Pirman
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biohaven Ltd. 8-K filings
Get the next BHVN 8-K as it lands
Follow BHVN for push alerts, or ask the research agent what this filing means.